ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Balance Sheet as at March 31, 2026

Particulars	Note No.	CAD (in Thousand)	
		As at March 31	
		2026	2025
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	1	523	562
Capital work-in-progress		172	-
Deferred Tax Assets [Net]		665	466
		1,360	1,028
Current Assets:			
Inventories	2	335	-
Financial Assets:			
Trade Receivables	3	223	-
Cash and Cash Equivalents	4	848	422
Other Current Assets	5	69	57
		1,475	479
Total		2,835	1,507
EQUITY AND LIABILITIES:			
Equity:			
Equity Share Capital	6	1,350	1,350
Other Equity	7	(1,840)	(1,321)
		(490)	29
Non-Current Liabilities:			
Financial Liabilities:			
Borrowings	8 [A]	-	862
Lease Liabilities		245	347
		245	1,209
Current Liabilities:			
Financial Liabilities:			
Borrowings	8 [B]	1,951	-
Lease Liabilities		102	95
Trade Payables	9	571	-
Other Financial Liabilities	10	439	174
Other Current Liabilities	11	18	-
		3,081	269
Total		2,836	1,507
Notes to the Financial Statements	1 to 18		

Statement of Profit and Loss for the Year ended March 31, 2026

Particulars	Note No.	CAD (in Thousand)	
		Year ended March 31	
		2026	2025
REVENUE:			
Revenue from Operations	12	2,349	-
Total Revenue		2,349	-
EXPENSES:			
Purchases of Stock-in-Trade	13	608	-
Changes in Inventories of Finished goods, Work-in-progress and Stock-in-Trade	14	(335)	-
Employee Benefits Expense	15	1,529	1,184
Finance Costs	16	85	17
Depreciation and Amortisation expenses	1	124	57
Other Expenses	17	1,022	404
Net Loss [Gain] on foreign currency transactions		34	24
Total Expenses		3,067	1,686
Loss before Tax		(718)	(1,686)
Less: Tax Expense:			
Current Tax		-	-
Deferred Tax		(199)	(439)
Loss for the year		(519)	(1,247)
OTHER COMPREHENSIVE INCOME:			
Other Comprehensive Income for the year, net of tax		-	-
Total Comprehensive Income for the year		(519)	(1,247)
Basic & Diluted Earning per Equity Share [EPS] [in CAD]	18	(0.92)	(2.21)
Notes to the Financial Statements	1 to 18		

For and on behalf of the Board

Sd/-

Director
Dated : May 15, 2026

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Statement of Change in Equity for the year ended March 31, 2026

a	**Equity Share Capital:**	**CAD (in Thousand)**	
		Year ended March 31	
		2026	2025
	Issued, Subscribed and Fully Paid-up Equity Shares:		
	563,657 Equity Shares	**1,350**	1,350
		1,350	1,350

b	**Other Equity:**	**Retained Earnings**	**Total**
		CAD (in Thousand)	
	As at March 31, 2024	**(74)**	**(74)**
	Add: Loss for the year	(1,247)	**(1,247)**
	As at March 31, 2025	**(1,321)**	**(1,321)**
	Add: Loss for the year	(519)	**(519)**
	As at March 31, 2026	**(1,840)**	**(1,840)**
			-

For and on behalf of the Board

Sd/-

Director
Dated : May 15, 2026

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Notes to the Financial Statements

Note: 1: Property, Plant and Equipment :

	Leasehold Buildings & Improvement	Furniture and Fixtures	Office Equipment	Computer Equipment	Total
			CAD (in Thousand)		
Gross Block:					
As at March 31, 2024	-	-	-	2	2
Additions	575	23	14	5	617
Disposals	-	-	-	-	-
As at March 31, 2025	575	23	14	7	619
Additions	16	26	35	8	85
Disposals	-	-	-	-	-
As at March 31, 2026	591	49	49	15	704
Depreciation and Impairment:					
As at March 31, 2024	-	-	-	-	-
Charge for the year	51	2	2	2	57
Disposals	-	-	-	-	-
As at March 31, 2025	51	2	2	2	57
Charge for the year	108	3	10	3	124
Disposals	-	-	-	-	-
As at March 31, 2026	159	5	12	5	181
Net Block:					
As at March 31, 2025	524	21	12	5	562
As at March 31, 2026	432	44	37	10	523

	CAD (in Thousand)	
	As at March 31	
	2026	2025
Note: 2-Inventories:		
[The Inventory is valued at lower of cost and net realisable value]		
Classification of Inventories:		
Stock-in-Trade	335	-
Total	335	-
Note: 3-Trade Receivables:		
Unsecured - Considered good	223	-
Total	223	-
Note: 4-Cash and Cash Equivalents:		
Balances with Banks	848	422
Total	848	422
Note: 5-Other Current Assets:		
[Unsecured, Considered Good]		
Balances with Statutory Authorities	28	7
Prepaid Expenses	41	50
Total	69	57

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Notes to the Financial Statements

	CAD (in Thousand)	
	As at March 31	
	2026	2025
Note: 6-Equity Share Capital:		
Issued, Subscribed and Fully Paid-up Equity Shares:		
563,657 [as at March 31, 2025: 563,657] Equity Shares	1,350	1,350
	1,350	1,350
Note: 7-Other Equity:		
Retained Earnings:		
Balance as per last Balance Sheet	(1,321)	(74)
Add: Loss for the year	(519)	(1,247)
Total	(1,840)	(1,321)
Note: 8 [A]-Non Current Borrowings:		
Term loan [From Related Party]		
Unsecured	-	862
Total	-	862
Note: 8 [B]-Non Current Borrowings:		
Term loan [From Related Party]		
Unsecured	1,951	862
Total	1,951	862
Note: 9-Trade Payables:		
Others	571	-
Total	571	-
Note: 10-Other Financial Liabilities:		
Accrued Expenses	439	-
Total	439	-
Note: 11-Other Current Liabilities:		
Others	18	174
Total	18	174
Note: 12-Revenue from Operations:		
Sale of Products	325	-
Other Operating Revenues:		
Miscellaneous Income	2,024	-
Total	2,349	-

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Notes to the Financial Statements

	CAD (in Thousand)	
	Year ended March 31	
	2026	2025
Note: 13-Purchases of Stock-in-Trade:		
Purchases of Stock-in-Trade	**608**	-
Total	**608**	-
Note: 14-Changes in Inventories:		
Stock at commencement:		
Stock-in-Trade	**-**	
	-	-
Less: Stock at close:		
Stock-in-Trade	**335**	-
	335	-
Total	**(335)**	-
Note: 15-Employee Benefits Expense:		
Salaries and wages	**1,495**	1,157
Contribution to provident and other funds	**33**	26
Staff welfare expenses	**-**	1
Total	**1,529**	1,184
Note: 16-Finance Cost:		
Interest expense	**78**	13
Bank commission & charges	**7**	4
Total	**85**	17
Note: 17-Other Expenses:		
Analytical Expenses	**16**	-
Rent	**28**	21
Repairs to Others	**6**	-
Insurance	**43**	16
Traveling Expenses	**112**	100
Legal and Professional Fees	**41**	-
Freight and forwarding on sales	**6**	-
Other marketing expenses	**172**	102
Miscellaneous Expenses	**598**	165
Total	**1,022**	404
Note: 18-Calculation of Earnings per Equity Share [EPS]:		
The numerators and denominators used to calculate the basic and diluted EPS are as follows:		
A Loss attributable to Shareholders	**(519)**	(1,247)
B Basic and weighted average number of Equity shares outstanding during the year — Numbers	**563,657**	563,657
	CAD	
C Nominal value of equity share	**100**	100
D Basic & Diluted EPS	**(0.92)**	(2.21)

Signatures to Notes 1 to 18 to the Financial Statements

For and on behalf of the Board

Sd/-

Director

Dated : May 15, 2026

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Cash Flow Statement for the year ended March 31, 2026

Particulars	**CAD- Thousands**	
	Year ended March 31	
	2026	2025
A Cash flows from operating activities:		
Loss after tax	**(519)**	(1,247)
Adjustments for:		
Depreciation, Impairment and Amortisation expenses	**124**	57
Income taxes	**(199)**	(439)
Foreign Exchange Loss (unrealised)	**34**	20
Interest expense	**78**	13
Total	**37**	(349)
Operating loss before working capital changes	**(482)**	(1,596)
Adjustments for:		
[Increase] in trade receivables	**(257)**	-
[Increase] in Inventories	**(336)**	-
Decrease/ [Increase] in other current assets	**(12)**	(57)
Iecrease in trade payables	**571**	-
Lease Liability	**(95)**	442
[Decrease] / Increase in other current liabilities	**280**	61
Total	**151**	446
Net cash used in operating activities	**(331)**	(1,150)
B Cash flows from investing activities:		
Purchase of Property, Plant and Equipment including payment of CWIP	**(257)**	(617)
Net cash from / [used in] investing activities	**(257)**	(617)
C Cash flows from financing activities:		
Proceeds from Issue of Common Share	**-**	1,350
Proceeds from non current borrowings		842
Proceeds from current borrowings	**1,089**	-
Interest paid	**(75)**	(3)
Net cash from financing activities	**1,014**	2,189
Net [Decrease] / Increase in cash and cash equivalents	**426**	422
Cash and cash equivalents at the beginning of the year	**422**	-
Cash and cash equivalents at the end of the year	**848**	422

Notes to the Cash Flow Statement

1 All figures in brackets are outflows.
2 Previous year's figures have been regrouped wherever necessary.

For and on behalf of the Board

Sd/-

Director
Dated : May 15, 2026